Table 2.
Main outcomes
| Author | Targeted drug | Mode of operation | mPAP or sPAP (mmHg) | PVR (Wu) | 6MWD (m) | SpO2 | Qp/Qs |
|---|---|---|---|---|---|---|---|
| Takaya et al. [9] | ERA\PDE5i\sGC\PC | intervention |
A:78.00 ± 26.00 B:38.00 ± 10.00 |
A:6.90 ± 3.20 B:3.20 ± 1.70 |
- - |
- - |
A:1.90 ± 0.80 - |
| Thomaz et al. [10] | PDE5i | – |
A:47.77 ± 14.77 B:25.27 ± 7.64 |
A:5.70 ± 3.69 B:2.97 ± 1.78 |
- - |
- - |
A:2.09 ± 1.02 B:2.43 ± 1.03 |
| Huang et al. [11] | ERA\PDE5i\PC | surgery |
A:70.5.0 ± 11.92 B:30.95 ± 10.92 |
A:20.51 ± 8.90 B:9.20 ± 3.63 |
- - |
- - |
- - |
| Hu et al. [12] | ERA\PDE5i\PC | valved patch repair |
A:79.61 ± 6.88 B:< 50 |
- - |
- - |
- - |
A:1.24 ± 0.21 - |
| ERA\PDE5i\PC | valved patch repair |
A:82.54 ± 6.49 B:59.05 ± 14.52 |
- - |
- - |
A:85.79 ± 2.29 B:91.13 ± 3.72 |
A:0.84 ± 0.13 - |
|
| Kijima et al. [13] | ERA\PDE5i\PC | intervention |
A:104.00 ± 27.00 B:40.00 ± 9.00 |
- - |
- - |
- - |
A:1.39 ± 0.41 - |
| Bradley et al. [14] | ERA\PDE5i\sGC\PC | – |
A:48.00 ± 13.00 B:36.63 ± 12.76 |
A:7.50 ± 4.30 B:5.05 ± 2.88 |
A:366 ± 137 B:486 ± 89 |
- - |
A:2.2 ± 1.5 B:1.11 ± 0.46 |
| Liuet al [15]. | ERA\PDE5i | surgery |
A:67.90 ± 9.90 B:22.50 ± 6.40 |
- - |
A:337.6 ± 23.3 B:424.6 ± 48.3 |
A:89.90 ± 2.10 B:97.30 ± 1.10 |
- - |
| He et al. [16] | ERA\PDE5i |
12 cases: intervention 2 cases: surgery |
A:57.10 ± 7.40 B:32.40 ± 14.10 |
A:8.70 ± 2.90 B:4.10 ± 2.70 |
- - |
- - |
A:1.40 ± 0.25 B:1.00 ± 0.00 |
| Liu et al. [8] | ERA\PDE5i | surgery |
A:64.90 ± 13.00 B:22.40 ± 8.70 |
- - |
- - |
- - |
- - |
A: Baseline; B: The last follow-up